76 related articles for article (PubMed ID: 15380359)
21. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
22. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
23. The effect of the membrane-proximal tyrosine-based sorting signal of HIV-1 gp41 on viral infectivity depends on sequences within gp120.
Day JR; Van Damme N; Guatelli JC
Virology; 2006 Oct; 354(2):316-27. PubMed ID: 16905171
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of DNA vaccine-induced immune responses by a 72-bp element from SV40 enhancer.
Li HS; Liu Y; Li DF; Zhang RR; Tang HL; Zhang YW; Huang W; Liu Y; Peng H; Xu JQ; Hong KX; Shao YM
Chin Med J (Engl); 2007 Mar; 120(6):496-502. PubMed ID: 17439744
[TBL] [Abstract][Full Text] [Related]
25. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
[TBL] [Abstract][Full Text] [Related]
26. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
27. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions.
Miyauchi K; Curran R; Matthews E; Komano J; Hoshino T; Engelman DM; Matsuda Z
Jpn J Infect Dis; 2006 Apr; 59(2):77-84. PubMed ID: 16632906
[TBL] [Abstract][Full Text] [Related]
28. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
29. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
30. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
[TBL] [Abstract][Full Text] [Related]
32. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.
Dosenovic P; Chakrabarti B; Soldemo M; Douagi I; Forsell MN; Li Y; Phogat A; Paulie S; Hoxie J; Wyatt RT; Karlsson Hedestam GB
J Immunol; 2009 Sep; 183(5):3373-82. PubMed ID: 19696434
[TBL] [Abstract][Full Text] [Related]
33. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.
Bosch V; Pfeiffer T; Devitt G; Allespach I; Ebensen T; Emerson V; Guzman CA; Keppler OT
Vaccine; 2009 Apr; 27(16):2202-12. PubMed ID: 19428834
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains.
Malinowsky K; Luksza J; Dittmar MT
Virology; 2008 Jun; 376(1):69-78. PubMed ID: 18400243
[TBL] [Abstract][Full Text] [Related]
35. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
Wingard JB; Anderson B; Weissman D
Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
[TBL] [Abstract][Full Text] [Related]
36. Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees.
Rovinski B; Dekaban GA; Cao SX; Yao FL; Persson R; Matthews TJ; Klein MH
Virology; 1999 May; 257(2):438-48. PubMed ID: 10329554
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.
Egan MA; Carruth LM; Rowell JF; Yu X; Siliciano RF
J Virol; 1996 Oct; 70(10):6547-56. PubMed ID: 8794289
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine-based YXXØ targeting motif of murine leukemia virus envelope glycoprotein affects pathogenesis.
Danis C; Deschambeault J; Do Carmo S; Cohen EA; Rassart E; Lemay G
Virology; 2004 Jun; 324(1):173-83. PubMed ID: 15183064
[TBL] [Abstract][Full Text] [Related]
39. Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.
West JT; Weldon SK; Wyss S; Lin X; Yu Q; Thali M; Hunter E
J Virol; 2002 Apr; 76(7):3338-49. PubMed ID: 11884559
[TBL] [Abstract][Full Text] [Related]
40. Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity.
Bhakta SJ; Shang L; Prince JL; Claiborne DT; Hunter E
Retrovirology; 2011 May; 8():37. PubMed ID: 21569545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
